Certara stock rating initiated at Equalweight by Morgan Stanley

Morgan Stanley initiated coverage on Certara Inc. (CERT) with an Equalweight rating and a $16.00 price target, projecting $420 million in FY2025 revenue with 9% year-over-year growth. This follows Certara's strong Q1 2025 results, which saw revenue increase 10% to $106 million and adjusted EBITDA rise 20% to $34.8 million, exceeding analyst expectations. Barclays subsequently upgraded Certara to Overweight, while the company also announced a $100 million share repurchase program. Certara is strategically positioned to benefit from the FDA's shift away from animal testing towards in silico tools, underscoring its continued momentum in the biosimulation market.

Analysis

Certara Inc. presents a mixed but compelling profile following recent developments. Morgan Stanley's initiation of coverage with an 'Equalweight' rating and a $16 price target establishes a neutral valuation benchmark. This contrasts with the company's strong first-quarter 2025 results, which surpassed expectations with a 10% year-over-year revenue increase to $106 million and a notable 20% rise in adjusted EBITDA to $34.8 million. Analyst sentiment is divided, with Barclays upgrading the stock to 'Overweight' on its performance, while JMP Securities maintains a 'Market Perform' rating. The company's financial position appears solid, underscored by a 'GOOD' financial health score from InvestingPro, strong cash flow, and a newly announced $100 million share repurchase program. A key long-term catalyst is the regulatory shift by the FDA away from animal testing towards in silico tools, which directly benefits Certara's core biosimulation business. Investors should also note the ongoing strategic review of its regulatory services unit, which could lead to a sharpening of its business focus, and Morgan Stanley's forecast for FY2025 which implies an acceleration in software revenue growth relative to services.

Key Decisions for Investors

• Investors should weigh the company's strong Q1 2025 earnings beat and positive regulatory tailwinds against the mixed analyst sentiment, typified by Morgan Stanley's neutral 'Equalweight' initiation.
• Monitor developments from the strategic review of the regulatory services business, as a potential divestiture could unlock value and streamline focus on the higher-growth biosimulation software segment.
• The $100 million share repurchase program may provide downside support, but its impact should be assessed relative to the company's $1.86 billion market capitalization and projected 9% revenue growth.
• Long-term holders should view the FDA's phase-out of animal testing as the primary thesis driver and watch for further signs of adoption of computational modeling to validate Certara's market position.